New Risk • May 20
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 24% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 24% per year for the foreseeable future. Minor Risk Large one-off items impacting financial results. Reported Earnings • May 17
First quarter 2026 earnings released: EPS: CA$0.003 (vs CA$0.009 in 1Q 2025) First quarter 2026 results: EPS: CA$0.003 (down from CA$0.009 in 1Q 2025). Revenue: CA$39.8m (up 22% from 1Q 2025). Net income: CA$3.47m (down 71% from 1Q 2025). Profit margin: 8.7% (down from 37% in 1Q 2025). Revenue is forecast to grow 5.5% p.a. on average during the next 2 years, compared to a 7.7% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has increased by 111% per year, which means it is tracking significantly ahead of earnings growth. Announcement • May 07
Auxly Cannabis Group Inc. to Report Q1, 2026 Results on May 14, 2026 Auxly Cannabis Group Inc. announced that they will report Q1, 2026 results Pre-Market on May 14, 2026 Announcement • Apr 28
Auxly Cannabis Group Inc., Annual General Meeting, Jun 30, 2026 Auxly Cannabis Group Inc., Annual General Meeting, Jun 30, 2026. Location: ontario, toronto Canada Recent Insider Transactions • Apr 07
Chief Financial Officer recently bought CA$102k worth of stock On the 30th of March, Travis Wong bought around 755k shares on-market at roughly CA$0.14 per share. This transaction amounted to 65% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Travis' only on-market trade for the last 12 months. New Risk • Mar 29
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 38% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 38% per year for the foreseeable future. Minor Risk Large one-off items impacting financial results. Reported Earnings • Mar 27
Full year 2025 earnings: Revenues and EPS in line with analyst expectations Full year 2025 results: EPS: CA$0.031 (up from CA$0.014 loss in FY 2024). Revenue: CA$151.5m (up 24% from FY 2024). Net income: CA$41.9m (up CA$58.2m from FY 2024). Profit margin: 28% (up from net loss in FY 2024). Revenue is forecast to grow 6.5% p.a. on average during the next 2 years, compared to a 8.6% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 99% per year but the company’s share price has only increased by 91% per year, which means it is significantly lagging earnings growth. Buy Or Sell Opportunity • Mar 26
Now 27% undervalued after recent price drop Over the last 90 days, the stock has fallen 10% to CA$0.13. The fair value is estimated to be CA$0.18, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Meanwhile, the company has become profitable. Buy Or Sell Opportunity • Dec 23
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 3.3% to CA$0.14. The fair value is estimated to be CA$0.19, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Meanwhile, the company has become profitable. Buy Or Sell Opportunity • Nov 20
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 9.4% to CA$0.14. The fair value is estimated to be CA$0.19, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Meanwhile, the company has become profitable. Reported Earnings • Nov 16
Third quarter 2025 earnings released: EPS: CA$0.015 (vs CA$0.003 in 3Q 2024) Third quarter 2025 results: EPS: CA$0.015 (up from CA$0.003 in 3Q 2024). Revenue: CA$39.9m (up 20% from 3Q 2024). Net income: CA$20.5m (up CA$17.3m from 3Q 2024). Profit margin: 51% (up from 9.7% in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has increased by 120% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Nov 06
Auxly Cannabis Group Inc. to Report Q3, 2025 Results on Nov 13, 2025 Auxly Cannabis Group Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 13, 2025 Recent Insider Transactions • Aug 20
CEO & Director recently bought CA$75k worth of stock On the 19th of August, Hugo Alves bought around 440k shares on-market at roughly CA$0.17 per share. This transaction amounted to 1.0% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth CA$149k. Hugo has been a buyer over the last 12 months, purchasing a net total of CA$251k worth in shares. Reported Earnings • Aug 15
Second quarter 2025 earnings released: EPS: CA$0.006 (vs CA$0.002 in 2Q 2024) Second quarter 2025 results: EPS: CA$0.006 (up from CA$0.002 in 2Q 2024). Revenue: CA$38.8m (up 33% from 2Q 2024). Net income: CA$8.31m (up 315% from 2Q 2024). Profit margin: 21% (up from 6.9% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth. Announcement • Aug 06
Auxly Cannabis Group Inc. to Report Q2, 2025 Results on Aug 14, 2025 Auxly Cannabis Group Inc. announced that they will report Q2, 2025 results Pre-Market on Aug 14, 2025 Recent Insider Transactions • Jun 29
CEO & Director recently bought CA$149k worth of stock On the 26th of June, Hugo Alves bought around 2m shares on-market at roughly CA$0.09 per share. This transaction amounted to 3.9% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Hugo has been a buyer over the last 12 months, purchasing a net total of CA$176k worth in shares. Reported Earnings • May 15
First quarter 2025 earnings released: EPS: CA$0.009 (vs CA$0.026 loss in 1Q 2024) First quarter 2025 results: EPS: CA$0.009 (up from CA$0.026 loss in 1Q 2024). Revenue: CA$32.7m (up 29% from 1Q 2024). Net income: CA$12.1m (up CA$38.1m from 1Q 2024). Profit margin: 37% (up from net loss in 1Q 2024). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Announcement • May 07
Auxly Cannabis Group Inc. to Report Q1, 2025 Results on May 15, 2025 Auxly Cannabis Group Inc. announced that they will report Q1, 2025 results at 9:30 AM, US Eastern Standard Time on May 15, 2025 Announcement • Apr 21
Auxly Cannabis Group Inc., Annual General Meeting, Jun 30, 2025 Auxly Cannabis Group Inc., Annual General Meeting, Jun 30, 2025. Location: ontario, toronto Canada Reported Earnings • Mar 20
Full year 2024 earnings released: CA$0.014 loss per share (vs CA$0.045 loss in FY 2023) Full year 2024 results: CA$0.014 loss per share (improved from CA$0.045 loss in FY 2023). Revenue: CA$122.3m (up 21% from FY 2023). Net loss: CA$16.3m (loss narrowed 63% from FY 2023). Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. Announcement • Mar 12
Auxly Cannabis Group Inc. to Report Q4, 2024 Results on Mar 20, 2025 Auxly Cannabis Group Inc. announced that they will report Q4, 2024 results Pre-Market on Mar 20, 2025 New Risk • Feb 21
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 30% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Shareholders have been substantially diluted in the past year (30% increase in shares outstanding). Minor Risk Market cap is less than US$100m (CA$78.9m market cap, or US$55.6m). Reported Earnings • Nov 09
Third quarter 2024 earnings released: EPS: CA$0.003 (vs CA$0.033 in 3Q 2023) Third quarter 2024 results: EPS: CA$0.003 (down from CA$0.033 in 3Q 2023). Revenue: CA$33.3m (up 18% from 3Q 2023). Net income: CA$3.24m (down 90% from 3Q 2023). Profit margin: 9.7% (down from 116% in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings. Announcement • Oct 31
Auxly Cannabis Group Inc. to Report Q3, 2024 Results on Nov 08, 2024 Auxly Cannabis Group Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 08, 2024 Reported Earnings • Aug 16
Second quarter 2024 earnings released: EPS: CA$0.002 (vs CA$0.013 loss in 2Q 2023) Second quarter 2024 results: EPS: CA$0.002 (up from CA$0.013 loss in 2Q 2023). Revenue: CA$29.2m (up 33% from 2Q 2023). Net income: CA$2.00m (up CA$14.9m from 2Q 2023). Profit margin: 6.9% (up from net loss in 2Q 2023). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings. Announcement • Aug 08
Auxly Cannabis Group Inc. to Report Q2, 2024 Results on Aug 15, 2024 Auxly Cannabis Group Inc. announced that they will report Q2, 2024 results Pre-Market on Aug 15, 2024 Reported Earnings • May 13
First quarter 2024 earnings released: CA$0.026 loss per share (vs CA$0.011 loss in 1Q 2023) First quarter 2024 results: CA$0.026 loss per share (further deteriorated from CA$0.011 loss in 1Q 2023). Revenue: CA$25.2m (up 5.3% from 1Q 2023). Net loss: CA$26.0m (loss widened 154% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings. Announcement • May 09
Auxly Cannabis Group Inc. to Report Q1, 2024 Results on May 13, 2024 Auxly Cannabis Group Inc. announced that they will report Q1, 2024 results Pre-Market on May 13, 2024 Announcement • Apr 26
Auxly Cannabis Group Inc., Annual General Meeting, Jun 28, 2024 Auxly Cannabis Group Inc., Annual General Meeting, Jun 28, 2024. New Risk • Apr 02
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 24% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (44% average weekly change). Minor Risks Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (CA$68.7m market cap, or US$50.6m). Reported Earnings • Mar 25
Full year 2023 earnings released: CA$0.045 loss per share (vs CA$0.15 loss in FY 2022) Full year 2023 results: CA$0.045 loss per share (improved from CA$0.15 loss in FY 2022). Revenue: CA$101.1m (up 7.0% from FY 2022). Net loss: CA$44.5m (loss narrowed 66% from FY 2022). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 55% per year, which means it is significantly lagging earnings. Announcement • Mar 19
Auxly Cannabis Group Inc. to Report Q4, 2023 Results on Mar 25, 2024 Auxly Cannabis Group Inc. announced that they will report Q4, 2023 results at 9:30 AM, US Eastern Standard Time on Mar 25, 2024 Reported Earnings • Nov 15
Third quarter 2023 earnings released: EPS: CA$0.033 (vs CA$0.067 loss in 3Q 2022) Third quarter 2023 results: EPS: CA$0.033 (up from CA$0.067 loss in 3Q 2022). Revenue: CA$28.2m (up 42% from 3Q 2022). Net income: CA$32.6m (up CA$92.7m from 3Q 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Announcement • Nov 07
Auxly Cannabis Group Inc. to Report Q3, 2023 Results on Nov 13, 2023 Auxly Cannabis Group Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 13, 2023 Board Change • Nov 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. Independent Director Vikram Bawa was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. New Risk • Oct 26
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: CA$15.2m (US$11.0m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$7.6m free cash flow). Share price has been highly volatile over the past 3 months (43% average weekly change). Earnings have declined by 10% per year over the past 5 years. Market cap is less than US$10m (CA$15.2m market cap, or US$11.0m). Minor Risk Shareholders have been diluted in the past year (11% increase in shares outstanding). New Risk • Aug 18
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$7.6m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$7.6m free cash flow). Share price has been highly volatile over the past 3 months (35% average weekly change). Earnings have declined by 10% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (CA$15.1m market cap, or US$11.2m). Reported Earnings • Aug 14
Second quarter 2023 earnings released: CA$0.013 loss per share (vs CA$0.016 loss in 2Q 2022) Second quarter 2023 results: CA$0.013 loss per share (improved from CA$0.016 loss in 2Q 2022). Revenue: CA$22.0m (down 20% from 2Q 2022). Net loss: CA$12.9m (loss narrowed 10.0% from 2Q 2022). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 55% per year, which means it is significantly lagging earnings. Announcement • Aug 09
Auxly Cannabis Group Inc. to Report Q2, 2023 Results on Aug 14, 2023 Auxly Cannabis Group Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 14, 2023 Announcement • Jul 28
Auxly Cannabis Group Inc. Announces Executive Changes Auxly Cannabis Group Inc. announced the resignation of Mr. Brian Schmitt from his position as Chief Financial Officer ("CFO") of Auxly, effective July 26, 2023. Mr. Schmitt is leaving for an opportunity outside of the cannabis industry at a non-reporting issuer. Travis Wong, Auxly's Senior Vice President of Finance, has been appointed interim CFO of Auxly effective immediately. Mr. Wong joined Auxly in 2017 and currently holds the position of Senior Vice President of Finance where he has been responsible for managing Auxly's day-to- day finance activities. Mr. Wong has more than 15 years of corporate finance, accounting and capital markets experience. Prior to joining Auxly, he worked as a natural resources investment banker at Nomura Securities based in London, England. He has advised on over $5bn of public and private M&A transactions and has been involved in capital raising transactions for a broad range of European corporations. Earlier in his career, he held positions at KPMG LLP in their audit and deal advisory teams. He is a Chartered Professional Accountant (CPA Canada), and holds a Bachelor of Business Administration from Simon Fraser University and an MBA from the University of Oxford. Reported Earnings • May 16
First quarter 2023 earnings released: CA$0.011 loss per share (vs CA$0.047 loss in 1Q 2022) First quarter 2023 results: CA$0.011 loss per share (improved from CA$0.047 loss in 1Q 2022). Revenue: CA$24.0m (up 5.9% from 1Q 2022). Net loss: CA$10.2m (loss narrowed 74% from 1Q 2022). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Pharmaceuticals industry in Canada. Announcement • May 09
Auxly Cannabis Group Inc. to Report Q1, 2023 Results on May 15, 2023 Auxly Cannabis Group Inc. announced that they will report Q1, 2023 results at 9:30 AM, US Eastern Standard Time on May 15, 2023 Reported Earnings • Apr 02
Full year 2022 earnings released: CA$0.15 loss per share (vs CA$0.059 loss in FY 2021) Full year 2022 results: CA$0.15 loss per share (further deteriorated from CA$0.059 loss in FY 2021). Revenue: CA$94.5m (up 13% from FY 2021). Net loss: CA$130.3m (loss widened 184% from FY 2021). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 61% per year, which means it is significantly lagging earnings. Announcement • Feb 16
Auxly Cannabis Group Inc. announced that it has received CAD 3.36 million in funding On February 15, 2023, Auxly Cannabis Group Inc. closed the transaction. Announcement • Feb 11
Auxly Cannabis Group Inc. announced that it expects to receive CAD 3.36 million in funding Auxly Cannabis Group Inc. announced that it has entered into agreement with an institutional investor for a private placement to issue 96,000,000 common shares at a price of CAD 0.035 per common share and and 96,000,000 common share purchase warrants with each warrant entitling the investors to purchase one common share at an exercise price of CAD 0.045 per common share for gross proceeds of CAD 3,360,000 on February 10, 2023. The transaction is expected to close on February 13, 2023. The transaction is subject to all necessary regulatory approvals, including the approval of the Toronto Stock Exchange. The securities issuable upon the exercise of the warrants will be offered on a private placement basis pursuant to exemptions from the registration requirements of the United States Securities Act of 1933, as amended, and certain other jurisdictions in accordance with applicable securities laws. No securities will be offered for sale or sold in Canada. Announcement • Feb 03
Morganti & Co. Issues Auxly Cannabis Group, Inc. Shareholder Class Action Notice of Certification On January 18, 2023, the Honourable Justice Morgan of the Ontario Superior Court of Justice certified the action: Relvas v. Auxly Cannabis Group Inc., Court File No.: CV-13-00617136-00CP (the Class Action) as a class proceeding against Auxly Cannabis Group Inc. and appointed Daniel Relvas as the representative plaintiff. The substance of the litigation has not been adjudicated by the Court (is that the Defendant made misrepresentations in its Management’s Discussion and Analysis and corresponding financial statement for the Three and Nine Months Ended September 30, 2018 on November 12, 2018, that were not publicly corrected until a news release on February 7, 2019). The Defendant denies the allegations. Class Members are automatically included in the action once certified if they do not opt-out. Investor do not need to do anything at this time to stay in the Class Action. If a settlement or any recovery or benefits are achieved for the Class and approved by the Court, investor will be notified about how to ask for the portion to which are entitled. Investor will be legally bound by all orders and judgments of the Court, and investor will not be able to sue the Defendant on investor own regarding the legal claims made in this case. Investor will NOT be required to pay any costs in the event that this Class Action is unsuccessful. All Class Members will be bound by all orders and judgments of the Court and any settlement reached unless they opt-out of the action. If investor wish to pursue own action or do not want to be bound by the outcome of the Class Action, then must opt-out of this Class Action and act prior to the expiration of the limitation periods. Major Estimate Revision • Nov 30
Consensus EPS estimates fall by 47% The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from CA$100.8m to CA$97.6m. Losses expected to increase from CA$0.09 per share to CA$0.14. Pharmaceuticals industry in Canada expected to see average net income growth of 4.2% next year. Consensus price target down from CA$0.10 to CA$0.092. Share price rose 39% to CA$0.025 over the past week. Reported Earnings • Nov 17
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Third quarter 2022 results: CA$0.067 loss per share (further deteriorated from CA$0.016 loss in 3Q 2021). Revenue: CA$19.8m (down 19% from 3Q 2021). Net loss: CA$60.1m (loss widened 344% from 3Q 2021). Revenue missed analyst estimates by 31%. Earnings per share (EPS) also missed analyst estimates. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Pharmaceuticals industry in Canada. Announcement • Nov 08
Auxly Cannabis Group Inc. to Report Q3, 2022 Results on Nov 14, 2022 Auxly Cannabis Group Inc. announced that they will report Q3, 2022 results Pre-Market on Nov 14, 2022 Reported Earnings • Aug 16
Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat Second quarter 2022 results: CA$0.016 loss per share (down from CA$0.005 loss in 2Q 2021). Revenue: CA$27.3m (up 31% from 2Q 2021). Net loss: CA$14.3m (loss widened 289% from 2Q 2021). Revenue exceeded analyst estimates by 20%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 19%, compared to a 26% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 57% per year, which means it is significantly lagging earnings. Announcement • Aug 11
An unknown buyer acquired Outdoor cultivation facility located in Hortonville, Nova Scotia from Auxly Cannabis Group Inc. (TSX:XLY) for CAD 4.1 million. An unknown buyer acquired Outdoor cultivation facility located in Hortonville, Nova Scotia from Auxly Cannabis Group Inc. (TSX:XLY) for CAD 4.1 million on August 10, 2022. The Company intends to apply the proceeds from both sales to support Auxly's ongoing operations.
An unknown buyer completed the acquisition of Outdoor cultivation facility located in Hortonville, Nova Scotia from Auxly Cannabis Group Inc. (TSX:XLY) on August 10, 2022. Major Estimate Revision • Aug 09
Consensus revenue estimates fall by 11% The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from CA$110.9m to CA$98.7m. Forecast losses increased from -CA$0.09 to -CA$0.10 per share. Pharmaceuticals industry in Canada expected to see average net income growth of 13% next year. Consensus price target down from CA$0.29 to CA$0.22. Share price rose 6.7% to CA$0.08 over the past week. Announcement • Aug 09
Auxly Cannabis Group Inc. to Report Q2, 2022 Results on Aug 15, 2022 Auxly Cannabis Group Inc. announced that they will report Q2, 2022 results Pre-Market on Aug 15, 2022 Major Estimate Revision • Jul 26
Consensus EPS estimates fall by 12% The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from CA$114.5m to CA$110.9m. Losses expected to increase from CA$0.08 per share to CA$0.09. Pharmaceuticals industry in Canada expected to see average net income growth of 13% next year. Consensus price target down from CA$0.33 to CA$0.29. Share price was steady at CA$0.07 over the past week. Announcement • Jul 06
An unknown buyer acquired Auxly Annapolis Inc from Auxly Cannabis Group Inc. (TSX:XLY) for CAD 6 million. An unknown buyer acquired Auxly Annapolis Inc from Auxly Cannabis Group Inc. (TSX:XLY) for CAD 6 million on July 5, 2022. Auxly Cannabis Group Inc. intends to apply the proceeds from the sale to support Auxly's ongoing operations.
An unknown buyer completed the acquisition of Auxly Annapolis Inc from Auxly Cannabis Group Inc. (TSX:XLY) on July 5, 2022. Major Estimate Revision • May 23
Consensus revenue estimates fall by 15% The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from CA$134.5m to CA$114.5m. Forecast losses increased from -CA$0.08 to -CA$0.08 per share. Pharmaceuticals industry in Canada expected to see average net income growth of 2.4% next year. Consensus price target down from CA$0.41 to CA$0.33. Share price fell 16% to CA$0.13 over the past week. Announcement • May 18
Auxly Cannabis Group Inc. Reports Impairment Changes for the First Quarter Ended March 31, 2022 Auxly Cannabis Group Inc. reported impairment changes for the first quarter ended March 31, 2022. For the quarter, the company reported impairment of long-term assets of $12,884,000. Impairment of intangible assets and goodwill was $10,789,000. Reported Earnings • May 16
First quarter 2022 earnings: EPS and revenues miss analyst expectations First quarter 2022 results: CA$0.047 loss per share (down from CA$0.015 loss in 1Q 2021). Revenue: CA$22.6m (up 126% from 1Q 2021). Net loss: CA$39.8m (loss widened 280% from 1Q 2021). Revenue missed analyst estimates by 11%. Earnings per share (EPS) also missed analyst estimates by 150%. Over the next year, revenue is forecast to grow 48%, compared to a 88% growth forecast for the industry in Canada. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings. Announcement • May 12
Auxly Cannabis Group Inc. to Report Q1, 2022 Results on May 16, 2022 Auxly Cannabis Group Inc. announced that they will report Q1, 2022 results Pre-Market on May 16, 2022 Price Target Changed • May 07
Price target decreased to CA$0.41 Down from CA$0.53, the current price target is an average from 4 analysts. New target price is 159% above last closing price of CA$0.16. Stock is down 57% over the past year. The company is forecast to post a net loss per share of CA$0.08 next year compared to a net loss per share of CA$0.059 last year. Announcement • Apr 23
Auxly Cannabis Group Inc., Annual General Meeting, Jun 30, 2022 Auxly Cannabis Group Inc., Annual General Meeting, Jun 30, 2022. Announcement • Feb 08
Auxly Cannabis Group Inc. Announces Close of Robinsons Cultivation Facilities Auxly Cannabis Group Inc. announced that the company has closed its Robinsons cultivation facilities located in Kentville and Hortonville, Nova Scotia, as the company continues to focus its efforts on streamlining and simplifying its cultivation platform. Announcement • Jan 25
KSM Securities Litigation Group Announces Ontario Court Grants Leave to Shareholders to Advance Statutory Claim Against Auxly Cannabis Securities Class Action KSM Securities Litigation Group announced that on November 2, 2021, the Superior Court of Justice, Divisional Court denied Auxly Cannabis Group’s motion to appeal the decision that authorized an investor in a proposed class action styled as Gowanlock v. Auxly Cannabis Group Inc., CV-19-00617136-00CP, to proceed with a statutory cause of action pursuant to section 138.3 of the Ontario Securities Act. The investor alleges that between November 12, 2018, and February 6, 2019, Auxly Cannabis Group Inc. released statements to the market that contained misrepresentations by omitting that its cannabis production facility it enjoyed an ownership interest with FSD Pharma Inc. was materially behind schedule and that its relationship with FSD Pharma Inc. was falling apart. The investor further alleges that on February 7, 2019, Auxly Cannabis Group released a statement that corrected the alleged misrepresentation announcing that it was ceasing its relationship with FSD Pharma Inc. The investor must amend the statement of claim to include the statutory cause of action, certify the cause of action with common issues for all investors, proceed into discovery of Auxly Cannabis Group’s books-and-records, and, ultimately, engage in a trial. If granted class certification status, investors’ shares purchased between November 12, 2018, and February 6, 2019, will be protected by this shareholder class action. Price Target Changed • Jan 19
Price target increased to CA$0.55 Up from CA$0.51, the current price target is an average from 5 analysts. New target price is 222% above last closing price of CA$0.17. Stock is down 60% over the past year. The company is forecast to post a net loss per share of CA$0.03 next year compared to a net loss per share of CA$0.14 last year. Breakeven Date Change • Jan 02
Forecast to breakeven in 2024 The 5 analysts covering Auxly Cannabis Group expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of CA$14.4m in 2024. Average annual earnings growth of 63% is required to achieve expected profit on schedule. Announcement • Nov 24
Auxly Cannabis Group Inc. (TSX:XLY) acquired Sunens Farms Inc. from Peter Quiring for CAD 5 million. Auxly Cannabis Group Inc. (TSX:XLY) acquired Sunens Farms Inc. from Peter Quiring for CAD 5 million on November 22, 2021. Under the agreement, Auxly acquired Sunens for consideration of (i) CAD 1.6 million, comprised of CAD 0.5 million in cash and CAD 1.1 million in Auxly common shares; (ii) CAD 3.4 million unsecured promissory note payable over 30 months in equal monthly installments with the first payment due 12 months after the date of closing and; (iii) the transfer of certain non-core assets of Sunens. Auxly remains focused on bringing new, innovative branded cannabis products to Canadian consumers and believe that this Acquisition will allow for continued growth, improved cost structure and near-term positive adjusted EBITDA.
Auxly Cannabis Group Inc. (TSX:XLY) copleted the acquisition of Sunens Farms Inc. from Peter Quiring on November 22, 2021. Price Target Changed • Nov 18
Price target decreased to CA$0.51 Down from CA$0.56, the current price target is an average from 4 analysts. New target price is 92% above last closing price of CA$0.27. Stock is down 33% over the past year. The company is forecast to post a net loss per share of CA$0.02 next year compared to a net loss per share of CA$0.14 last year. Reported Earnings • Nov 18
Third quarter 2021 earnings released: CA$0.016 loss per share (vs CA$0.028 loss in 3Q 2020) The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: CA$24.5m (up 82% from 3Q 2020). Net loss: CA$13.5m (loss narrowed 24% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings. Price Target Changed • Aug 18
Price target increased to CA$0.50 Up from CA$0.46, the current price target is an average from 4 analysts. New target price is 96% above last closing price of CA$0.26. Stock is up 16% over the past year. Reported Earnings • Aug 18
Second quarter 2021 earnings released: CA$0.005 loss per share (vs CA$0.046 loss in 2Q 2020) The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: CA$20.9m (up 204% from 2Q 2020). Net loss: CA$3.68m (loss narrowed 87% from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings. Major Estimate Revision • Aug 17
Consensus forecasts updated The consensus outlook for 2021 has been updated. 2021 revenue forecast increased from CA$67.8m to CA$75.3m. EPS estimate unchanged from -CA$0.045 at last update. Pharmaceuticals industry in Canada expected to see average net income growth of 37% next year. Consensus price target of CA$0.46 unchanged from last update. Share price rose 13% to CA$0.26 over the past week. Announcement • Jul 14
Auxly Cannabis Group Inc. on Hot Streak Heading into Summer Packed with New Products Auxly Cannabis Group Inc. presented its product line-up for a summer season filled with brand-new offerings and inspired flavours across multiple categories, including dried flower, vapes, edibles, oil, capsules and concentrates. announcement comes as the Company is experiencing success with its previously announced strategic expansion into the dried flower market, including the introduction of dried flower offerings under its Back Forty brand. Auxly’s Back Forty Pine Kush launched in March and it has quickly become one of the most popular flower brands in Canadai. The success of the Back Forty flower launch has helped Auxly capture approximately 2% of the entire national cannabis flower market (dried flower and pre-rollsii) for the month of June. The Company is delighted with its early success in a segment (dried flower) that accounts for nearly 75% of all Canadian cannabis sales to-date this quarter, or more than $2 billion in sales annually. With its leadership position in cannabis 2.0 products and the added success of dried flower sales, Auxly has achieved a 5.2% share of the national market for the month of June, as confirmed by Headset Canadian Insights. Further, the Company has moved up to the #6 position among Canadian Licensed Producers for the month of June. Now, Auxly looks ahead to a summer 2021 lineup designed to delight Canadian cannabis consumers and capture even more of the dried flower market, including new cultivars under the Back Forty brand and the launch of Back Forty pre-rolls. Back Forty Animal Mints and Wedding Pie flower. Organically grown, Animal Mints and Wedding Pie are exceptional strains with high THC potencies. These new cultivars will land in the Back Forty where consumers find a better experience for less. Back Forty 40s pre-rolls. 40s are machine-rolled straight joints manufactured with state-of-the-art pre-roll technology for a consistent, quality pre-roll that burns evenly with enhanced airflow and flavour. Back Forty 40s will launch with Back Forty’s new organically grown strains Animal Mints and Wedding Pie. Kolab Project x Robinsons Growers Series Purple Kush. This summer crossover sees Robinsons’ heavy hitting Purple Kush joining the popular Kolab Project Growers Series, providing cannabis enthusiasts with Robinsons’ superior quality cannabis uplifted by the Kolab Project Growers Series platform. Announcement • Jun 16
Auxly Cannabis Group Inc. has completed a Composite Units Offering in the amount of CAD 15.0003 million. Auxly Cannabis Group Inc. has completed a Composite Units Offering in the amount of CAD 15.0003 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 47,620,000
Price\Range: CAD 0.315
Discount Per Security: CAD 0.0189
Transaction Features: Rule 144A Recent Insider Transactions • Jun 16
CEO & Director recently bought CA$169k worth of stock On the 14th of June, Hugo Alves bought around 664k shares on-market at roughly CA$0.25 per share. This was the largest purchase by an insider in the last 3 months. This was Hugo's only on-market trade for the last 12 months. Major Estimate Revision • Jun 08
Consensus EPS estimates fall to -CA$0.05 The consensus outlook for earnings per share (EPS) in 2021 has deteriorated. 2021 revenue forecast decreased from CA$69.6m to CA$67.8m. Losses expected to increase from -CA$0.043 to -CA$0.05. Pharmaceuticals industry in Canada expected to see average net income growth of 120% next year. Consensus price target of CA$0.52 unchanged from last update. Share price fell 5.5% to CA$0.34 over the past week. 
